Company Filing History:
Years Active: 2000
Title: Michimasa Hirata: Innovator in Cationic Protein Research
Introduction
Michimasa Hirata is a notable inventor based in Morioka, Japan. He has made significant contributions to the field of biomedical research, particularly in the area of cationic proteins and their applications in treating various medical conditions. With a total of two patents to his name, Hirata's work has the potential to impact the treatment of lipopolysaccharide-related conditions and coagulant-related diseases.
Latest Patents
Hirata's latest patents include innovations related to mammalian cationic proteins that bind to lipopolysaccharides. These patents describe compositions and methods for diagnosing and treating conditions associated with lipopolysaccharides and coagulation disorders. The compositions feature polypeptides that are identical or homologous to a specific cationic protein known as CAP18, which is derived from mammalian granulocytes. Notably, these polypeptides can bind to lipopolysaccharides and inhibit their activation of macrophages, as well as interfere with the clotting cascade, which is crucial in conditions like disseminated intravascular coagulation.
Career Highlights
Throughout his career, Michimasa Hirata has worked with prominent organizations such as Seikagaku Corporation and Panorama Research Inc. His research has focused on developing therapeutic solutions that leverage the properties of antimicrobial peptides. His innovative approach has garnered attention in the scientific community and has the potential to lead to significant advancements in medical treatments.
Collaborations
Hirata has collaborated with esteemed colleagues, including James W. Larrick and Susan C. Wright. These partnerships have facilitated the exchange of ideas and expertise, further enhancing the impact of his research.
Conclusion
In summary, Michimasa Hirata is a distinguished inventor whose work in cationic protein research has led to valuable patents and potential medical advancements. His contributions continue to shape the landscape of biomedical innovation.